• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Ashish K. Kulkarni as new director

    5/8/24 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024.  Prior to Celanese, Kulkarni held leadership positions at United Technologies Corporation, American Standard and General Electric.

    With the addition of Kulkarni and in anticipation of potential director retirements under the Board's retirement and resignation policy, Ashland increases the size of the Board to 11 members.

    Kulkarni is a highly experienced global technology and innovation leader in premier companies across diverse industries. He excels at building cultures and ecosystems of innovation to accelerate the delivery of breakthrough products and services that increase customer loyalty, market share, revenue growth, profitability, and return on investment (ROI).

    "I am pleased to welcome Ashish as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy to shape and grow our portfolio, Ashish will provide unique perspectives about advancing and accelerating scalable growth."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland may from time to time make forward-looking statements in its annual reports, quarterly reports and other filings with the SEC, news releases and other written and oral communications. These forward-looking statements are based on Ashland's expectations and assumptions, as of the date such statements are made. These statements include but may not be limited to, Ashland's current expectations or beliefs concerning, among other things, its future Board size. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These risks and uncertainties affecting Ashland are described in Ashland's most recent Form 10-K (including Item 1A Risk Factors) filed with the SEC, which is available on Ashland's website at http://investor.ashland.com or on the SEC's website at http://www.sec.gov. Various risks and uncertainties may cause actual results to differ materially from those stated, projected or implied by any forward-looking statements. Ashland believes its expectations and assumptions are reasonable, but there can be no assurance that the expectations reflected herein will be achieved. Unless legally required, Ashland undertakes no obligation to update any forward-looking statements made in this news release whether as a result of new information, future events or otherwise.

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    William WhitakerCarolmarie C. Brown
    +1 (614) 790-2095+1 (302) 995-3158
    [email protected][email protected]

    Attachment

    • Ashland_announces_new_board_member_REV_FNL_20240508


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH

    DatePrice TargetRatingAnalyst
    9/8/2025$60.00Equal-Weight
    Morgan Stanley
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    3/5/2025Buy → Neutral
    Seaport Research Partners
    8/8/2024$90.00 → $89.00Underweight → Neutral
    JP Morgan
    4/11/2024$100.00 → $112.00Equal Weight → Overweight
    Wells Fargo
    3/14/2024$100.00 → $126.00Hold → Buy
    Jefferies
    3/1/2024$108.00Outperform
    Wolfe Research
    More analyst ratings

    $ASH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Bishop Steven D

    4 - ASHLAND INC. (0001674862) (Issuer)

    10/2/25 4:30:10 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Chattopadhyay Sanat

    4 - ASHLAND INC. (0001674862) (Issuer)

    10/2/25 4:30:08 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SVP and GM, Life Sciences Assis Alessandra Faccin exercised 3,123 shares at a strike of $51.26 and covered exercise/tax liability with 1,327 shares, increasing direct ownership by 57% to 4,946 units (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    7/28/25 4:30:42 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SVP and GM, Life Sciences Assis Alessandra Faccin bought $201,600 worth of shares (3,150 units at $64.00) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:03 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    SEC Filings

    View All

    Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    11/4/25 5:07:51 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland Inc. filed SEC Form 8-K: Leadership Update

    8-K - ASHLAND INC. (0001674862) (Filer)

    9/18/25 4:30:27 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Ashland Inc.

    SCHEDULE 13G - ASHLAND INC. (0001674862) (Subject)

    8/14/25 10:48:33 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Ashland with a new price target

    Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00

    9/8/25 8:48:38 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland downgraded by Wells Fargo

    Wells Fargo downgraded Ashland from Overweight to Equal Weight

    5/1/25 3:02:01 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland upgraded by Analyst with a new price target

    Analyst upgraded Ashland from Neutral to Overweight and set a new price target of $71.00 from $68.00 previously

    3/26/25 7:45:24 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

      Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $50 million, or $1.08 per diluted shareNet income of $32 million, or $0.71 per diluted shareAdjusted EBITDA of $119 million, down four p

    11/4/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland changes start time for fourth-quarter fiscal 2025 earnings conference call webcast

    WILMINGTON, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has changed the start time of its fourth-quarter fiscal 2025 earnings webcast being held on Wednesday, November 5, 2025. The event will now begin at 10:00 a.m. ET instead of 9:00 a.m. ET.  Attendees that have previously registered do not need to register again. The company's live webcast with securities analysts will include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. To access the call by phone, please go to this registration link and you will be provided with dial in detail

    10/30/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland sets date for fourth-quarter fiscal 2025 earnings release and conference call webcast

    WILMINGTON, Del., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its fourth-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, November 4, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 5. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief

    10/23/25 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Financials

    Live finance-specific insights

    View All

    Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

      Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $50 million, or $1.08 per diluted shareNet income of $32 million, or $0.71 per diluted shareAdjusted EBITDA of $119 million, down four p

    11/4/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland changes start time for fourth-quarter fiscal 2025 earnings conference call webcast

    WILMINGTON, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has changed the start time of its fourth-quarter fiscal 2025 earnings webcast being held on Wednesday, November 5, 2025. The event will now begin at 10:00 a.m. ET instead of 9:00 a.m. ET.  Attendees that have previously registered do not need to register again. The company's live webcast with securities analysts will include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. To access the call by phone, please go to this registration link and you will be provided with dial in detail

    10/30/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland sets date for fourth-quarter fiscal 2025 earnings release and conference call webcast

    WILMINGTON, Del., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its fourth-quarter fiscal 2025 earnings release at approximately 5 p.m. ET on Tuesday, November 4, 2025. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Wednesday, November 5. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerWilliam Whitaker, senior vice president, and chief

    10/23/25 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Leadership Updates

    Live Leadership Updates

    View All

    Ashland announces executive leadership changes

    WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

    5/5/25 5:00:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Turnspire Capital Partners Completes Acquisition of Pharmachem from Ashland

    Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu

    9/3/24 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions

    Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio

    9/3/24 7:00:00 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary